List of Excipients in Branded Drug PROCHLORPERAZINE

« Back to Dashboard

Generic Drugs Containing PROCHLORPERAZINE

Company	Ingredient	NDC	Excipient
Cosette Pharmaceuticals Inc	prochlorperazine	0713-0135	GLYCERIN
Cosette Pharmaceuticals Inc	prochlorperazine	0713-0135	GLYCERYL MONOSTEARATE
Cosette Pharmaceuticals Inc	prochlorperazine	0713-0135	HYDROGENATED COCONUT OIL
Cosette Pharmaceuticals Inc	prochlorperazine	0713-0135	PALM KERNEL OIL
A-S Medication Solutions	prochlorperazine	50090-0636	GLYCERIN
A-S Medication Solutions	prochlorperazine	50090-0636	GLYCERYL MONOSTEARATE
A-S Medication Solutions	prochlorperazine	50090-0636	HYDROGENATED COCONUT OIL

What are the Most Frequently-Used Excipients in PROCHLORPERAZINE?

# Of NDCs	Excipient
2	ALUMINUM OXIDE
2	CELLULOSE, MICROCRYSTALLINE
2	D&C YELLOW NO. 10
2	FD&C BLUE NO. 2
2	FD&C YELLOW NO. 6
3	GLYCERIN
3	GLYCERYL MONOSTEARATE

Prochlorperazine Excipient Strategy and Commercial Opportunities

Last updated: October 6, 2026

Prochlorperazine is a mature phenothiazine drug with limited conventional patent protection and intense generic competition. The commercial opportunity is concentrated in differentiated dosage forms, reliable injectable supply, pediatric and geriatric administration, and excipient-controlled products rather than in a new active-ingredient franchise. Excipient selection should address taste, swallowability, stability, injection compatibility, allergen avoidance, and manufacturing cost.

What is the commercial status of prochlorperazine?

Prochlorperazine is marketed primarily as prochlorperazine maleate for oral and rectal administration and as prochlorperazine edisylate for injection. It is used for severe nausea and vomiting and, in some markets, schizophrenia and other psychotic disorders. In the United States, the drug is available through generic prescription products rather than a protected branded franchise.[1]

Attribute	Prochlorperazine
Drug class	Phenothiazine dopamine D2 antagonist
Principal active moieties	Prochlorperazine maleate; prochlorperazine edisylate
Common dosage forms	Tablets, suppositories, injectable solution
Main antiemetic competitors	Ondansetron, promethazine, metoclopramide, haloperidol
U.S. regulatory pathway	Primarily ANDA generic products
Biosimilar exposure	None; prochlorperazine is a small molecule
Orange Book strategy	Generic listings with limited current patent value
Main commercial constraints	Low unit price, safety warnings, generic substitution
Main differentiation paths	ODT, oral film, liquid, preservative-controlled injection, supply reliability

The product carries clinically important risks, including extrapyramidal symptoms, tardive dyskinesia, sedation, hypotension, anticholinergic effects, neuroleptic malignant syndrome, and QT-related concerns. Its labeling also includes the class warning against use in elderly patients with dementia-related psychosis.[2] Excipients cannot eliminate these pharmacologic risks, but they can improve administration and product reliability.

What excipients are used in current prochlorperazine products?

Excipient systems vary by manufacturer and dosage form. Generic labels commonly identify conventional tablet fillers, binders, disintegrants, lubricants, coating agents, and colorants. Injectable products require a separate strategy because pH, oxidation, sulfite sensitivity, particulate control, and container compatibility affect product quality.

Oral tablets

Typical excipient categories include:

Function	Potential excipient classes	Commercial purpose
Diluent	Lactose, microcrystalline cellulose, dicalcium phosphate	Controls tablet size and compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves mechanical strength
Disintegrant	Corn starch, crospovidone, croscarmellose sodium	Accelerates tablet breakup
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Supports high-speed tableting
Glidant	Colloidal silicon dioxide	Improves powder flow
Coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Improves handling, identification, and swallowability
Sweetener or flavor	Sucralose, mannitol, flavor systems	Relevant to rapidly disintegrating formats

Lactose-containing tablets may exclude patients with lactose intolerance, although the amount in a conventional tablet is generally low. A lactose-free product based on microcrystalline cellulose, mannitol, or dibasic calcium phosphate could provide a modest procurement and patient-access distinction.

Dye-free and titanium-dioxide-free tablets also have a commercial rationale in institutional purchasing and markets with tighter scrutiny of colorants. These changes may be technically simple but require separate formulation development, stability work, bioequivalence assessment where applicable, and regulatory documentation.

Suppositories

Rectal products generally use a fatty or water-miscible base. Hydrogenated vegetable oils, hard fats, polyethylene glycol mixtures, and related suppository bases can control melting, drug release, mechanical strength, and storage performance.

A suppository strategy should optimize:

• Softening and melting near body temperature.
• Uniform drug distribution during manufacture.
• Resistance to deformation during shipment.
• Limited leakage after administration.
• Release across a range of rectal conditions.
• Compatibility with blister or strip packaging.

The suppository is commercially relevant when oral administration is impractical because of active vomiting, dysphagia, reduced consciousness, or inability to retain oral medication. It is also a potential supply-reliability niche because fewer manufacturers may support rectal products than tablets.

Injectable solution

Prochlorperazine edisylate injection requires tighter control over solution chemistry and packaging. The formulation may include sodium chloride, water for injection, pH-adjusting agents, and sulfite-type antioxidants depending on the manufacturer and label. Specific composition must be verified against the current product label because generic formulations are not necessarily identical.[3]

Key injectable excipient issues include:

• Sulfite sensitivity and labeling.
• Oxidative degradation.
• Solution color and clarity.
• pH-driven precipitation.
• Adsorption to glass, elastomer, or polymer components.
• Extractables and leachables.
• Particulate formation.
• Compatibility with IV or IM administration conditions.
• Preservative concentration and multidose-container requirements.

A preservative-free, single-dose presentation could address hospital use and reduce preservative exposure. Its value would depend on manufacturing cost, container-closure performance, and purchasing contracts. A ready-to-administer syringe or premixed presentation could also create operational value, but the product would face higher development, packaging, and stability costs than a conventional vial.

What excipient strategy offers the strongest commercial opportunity?

The most attractive strategy is a differentiated product that solves an administration or supply problem without materially increasing regulatory complexity.

1. Orally disintegrating tablet

An ODT could target patients with nausea, dysphagia, or difficulty taking conventional tablets. Mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and suitable flavor systems are common development tools.

Critical performance targets include:

• Disintegration in approximately 30 seconds or less.
• Acceptable mouthfeel.
• Low friability.
• Adequate dose uniformity.
• Limited bitterness.
• Stability under ordinary humidity exposure.

Prochlorperazine has an inherent bitterness problem typical of many phenothiazines. Taste masking is therefore central. Polymer coating of drug particles, ion-exchange resins, cyclodextrins, lipid barriers, or multiparticulate encapsulation can reduce immediate bitterness. The trade-off is that excessive coating may delay dissolution and complicate bioequivalence.

2. Buccal or sublingual delivery

A buccal tablet, mucoadhesive film, or sublingual system could reduce swallowing requirements and potentially provide a differentiated route for patients actively vomiting. Mucoadhesive polymers may include hydroxypropyl methylcellulose, carbomers, polycarbophil, sodium alginate, or chitosan derivatives.

The commercial case is weaker than for an ODT unless the product demonstrates a clear administration advantage. A buccal system must control:

• Residence time.
• Local irritation.
• Drug release.
• Salivary washout.
• Dose uniformity.
• Taste and mucosal sensation.

A new transmucosal dosage form would likely require a more demanding regulatory package than a conventional generic tablet. Depending on the reference product and claims, a 505(b)(2) pathway may be more appropriate than a standard ANDA.

3. Oral liquid

An oral solution or suspension could serve pediatric, geriatric, and dysphagic patients. The formulation would require careful control of:

• Solubility or suspension particle size.
• pH and preservative efficacy.
• Chemical stability.
• Sedimentation and redispersibility.
• Sweetener and flavor acceptance.
• Measuring-device accuracy.
• Sugar-free and alcohol-free positioning.

Potential excipient systems include sorbitol, glycerin, propylene glycol, polyethylene glycol, xanthan gum, sodium benzoate, potassium sorbate, citric acid, and citrate buffers. Each excipient must be evaluated against pediatric-use expectations, local tolerability, and global regulatory limits.

A liquid product has a stronger differentiation rationale than another conventional tablet but may face dose-measurement and stability challenges. A unit-dose oral suspension could support hospital and emergency use but would increase packaging costs.

4. Preservative-controlled injection

An injectable product with a single-dose, preservative-free presentation could compete on hospital safety and operational simplicity. A ready-to-use syringe may reduce preparation time and dosing errors.

The product strategy should prioritize:

• Low extractables and leachables.
• Reliable stopper reseal or single-dose closure.
• Container compatibility.
• Protection from light and oxygen where necessary.
• Sterility assurance.
• Low particulate burden.
• Supply continuity.

This opportunity is commercially attractive only if the sponsor can secure hospital contracts or solve a recurring shortage or procurement problem. Price competition is severe for standard injectable generics.

What formulation patents could protect a prochlorperazine product?

A new prochlorperazine product is unlikely to obtain meaningful protection from a broad composition-of-matter patent because the active ingredient is old. Protection may instead arise from narrow formulation, manufacturing, packaging, or delivery claims.

Potential claim categories include:

Patent category	Possible protected subject matter	Commercial strength
ODT	Taste-masked particles, disintegration profile, excipient ratios	Moderate if difficult to design around
Buccal film	Mucoadhesive matrix, release profile, film structure	Moderate
Oral liquid	Stable pH range, suspension system, preservative combination	Low to moderate
Injection	Stabilized solution, oxygen control, container system	Moderate
Suppository	Base composition, release control, manufacturing process	Low to moderate
Manufacturing	Granulation, particle coating, blending, filling	Variable
Packaging	Ready-to-use syringe, moisture barrier, unit-dose system	Moderate
Method of use	Specific nausea or vomiting population	Usually limited for an old drug

Patent value depends on claim breadth and design-around risk. A narrow claim covering a particular excipient ratio has limited enforcement value if a competitor can use a different polymer, diluent, or process. A stronger estate would combine formulation claims with process, product-by-process, container, and method-of-use claims.

The sponsor should not rely on patent protection alone. Regulatory exclusivity, trade secrets covering coating or granulation processes, manufacturing scale-up know-how, and hospital contracting may provide more practical value than a narrow formulation patent.

When does prochlorperazine lose exclusivity?

Prochlorperazine’s core exclusivity expired decades ago. The current U.S. market is therefore driven by generic competition, not by remaining active-ingredient exclusivity. Generic applicants generally pursue ANDA approval where their product can match the reference product in dosage form, strength, route, quality, and bioequivalence.[4]

A genuinely new dosage form, route, or delivery system may support a 505(b)(2) application. The resulting product could qualify for regulatory exclusivity if it meets statutory requirements, but the scope would relate to the approved innovation rather than to prochlorperazine as a molecule.[5]

There is no biosimilar pathway because prochlorperazine is a chemically synthesized small molecule. Biosimilar competition is therefore not a relevant risk category.

What is the Orange Book status of prochlorperazine?

The FDA Orange Book is the relevant source for listed patents, exclusivity, reference products, and therapeutic-equivalence information.[4] Prochlorperazine products are primarily generic entries, and the commercial landscape is generally characterized by abbreviated applications rather than a branded patent dispute.

The practical Orange Book questions are:

1. Which prochlorperazine product is the reference listed drug?
2. Does the selected dosage form have a current patent or exclusivity code?
3. Are there therapeutic-equivalence ratings for competing strengths?
4. Does the proposed product match the reference route and dosage form?
5. Would a reformulated product require a 505(b)(2) application?

A sponsor should treat any current Orange Book status as product- and dosage-form-specific. Tablet, suppository, and injectable entries may have different reference products and different regulatory histories.

Are Paragraph IV challenges likely for prochlorperazine?

Paragraph IV litigation is unlikely to be commercially important for legacy conventional prochlorperazine products because the core patents have expired and the market already contains generic competition. A Paragraph IV filing becomes relevant if a new prochlorperazine formulation receives an Orange Book-listed patent.

Potential litigation targets would include:

• A newly approved ODT.
• A patented taste-masking platform.
• A long-acting or transmucosal delivery system.
• A proprietary ready-to-use injection.
• A formulation with a listed method-of-use patent.

The business risk would depend on whether the new formulation captures meaningful demand or merely shifts existing generic demand. For an old antiemetic, a patent covering a narrow excipient system may support licensing leverage but may not justify extensive litigation unless the product secures a differentiated clinical or procurement position.

Which companies are challenging prochlorperazine, and what is the litigation status?

The competitive challenge is primarily generic substitution rather than active branded patent litigation. Multiple generic manufacturers have historically supplied prochlorperazine products, subject to changing approvals, discontinuations, and supply conditions recorded in FDA databases and DailyMed labels.[1,3]

There is no established biosimilar challenge because the product is not biologic. A litigation review should focus on:

• FDA ANDA approvals and discontinuations.
• Drug shortage records for injectable products.
• Product-specific recalls.
• Orange Book patent listings.
• Federal court records for any formulation-specific dispute.
• Manufacturer supply commitments.

The most material commercial risk is likely low-margin generic competition and intermittent availability, especially for less commonly manufactured presentations.

How does prochlorperazine compare with competing antiemetics?

Product	Main strength	Excipient opportunity	Key commercial limitation
Prochlorperazine	Low-cost, multiple routes, established antiemetic use	ODT, liquid, suppository, injection reliability	Extrapyramidal and sedative effects
Ondansetron	Broad antiemetic use and strong patient familiarity	ODT, film, liquid, injectable	Generic competition and QT concerns
Promethazine	Oral, rectal, and injectable options	Oral liquid and rectal delivery	Sedation, tissue injury risk with injection
Metoclopramide	Antiemetic and prokinetic activity	Liquid and orally disintegrating formats	Tardive dyskinesia and duration limits
Haloperidol	Use in selected refractory nausea settings	Injectable and oral delivery	Antipsychotic safety profile and QT risk

Prochlorperazine’s strongest competitive position is low acquisition cost combined with route flexibility. Its weakest position is tolerability. Excipients can improve delivery but cannot remove the active ingredient’s adverse-effect profile.

What generic launch risks exist?

A conventional tablet launch faces limited technical risk but substantial commercial risk. The principal risks are:

• Low reimbursement and rapid price erosion.
• Multiple approved generic suppliers.
• Difficulty securing pharmacy shelf space.
• Limited switching incentive from established products.
• Manufacturing scale requirements despite low unit prices.
• Product-specific shortages or discontinuations.
• Competition from ondansetron and promethazine.

A differentiated ODT, buccal film, or oral liquid may support higher pricing, but the sponsor must demonstrate a practical benefit. A product that only changes flavor or excipient identity may have weak market pull.

What geographic opportunities exist?

The largest opportunity is usually not a single global excipient platform. Regulatory and commercial priorities differ by market.

United States

The U.S. opportunity is concentrated in ANDA products, hospital injectables, shortage-resistant supply, and 505(b)(2) reformulations. Orange Book and FDA labeling requirements govern the core regulatory analysis.[4,5]

Europe

European markets may offer opportunities for buccal, oral liquid, and suppository products where national formularies and hospital procurement reward specific dosage forms. Excipient acceptability, pediatric labeling, and local reimbursement are important.

Emerging markets

Cost-efficient tablets and stable suppositories may have stronger demand than premium delivery systems. Packaging must address heat, humidity, transport, and variable storage infrastructure. Lactose-free, sugar-free, and alcohol-free formulations can provide practical differentiation, but price remains decisive.

How strong is the patent estate for prochlorperazine?

The patent estate for the active ingredient is weak because prochlorperazine is an established generic drug. A new estate could be moderate if it protects a difficult-to-reproduce delivery system and is supported by manufacturing know-how.

The strongest defensible package would combine:

1. A clinically useful dosage-form advantage.
2. A formulation that is difficult to design around.
3. Process parameters maintained as trade secrets.
4. A reliable supply chain.
5. Regulatory exclusivity where available.
6. Hospital, specialty-pharmacy, or distributor contracts.

A tablet with a routine lactose-to-cellulose substitution is unlikely to create durable market power. A stable, taste-masked, rapidly disintegrating product with validated patient-use benefits has a better commercial profile.

What licensing deals are plausible?

Licensing opportunities are most likely in three areas:

• A proprietary taste-masking or particle-coating technology.
• A ready-to-use injectable or prefilled-syringe platform.
• A mucoadhesive buccal or oral-film delivery system.

An originator-style license for prochlorperazine itself is unlikely to be valuable because the active ingredient is generic. A platform license may be more practical, particularly if the technology can be applied to other bitter, low-dose, or poorly tolerated drugs.

Key Takeaways

• Prochlorperazine is a mature generic small molecule with no biosimilar risk.
• Conventional tablets offer limited commercial differentiation.
• The strongest excipient opportunities are ODT, taste-masked oral products, oral liquid, suppository, and supply-reliable injection.
• Injectable products require the highest control of sulfites, oxidation, pH, packaging, sterility, and particulates.
• Formulation patents can protect a new product, but narrow excipient claims are vulnerable to design-around.
• Paragraph IV litigation is unlikely for legacy products and becomes relevant mainly after approval of a new patented formulation.
• Commercial success depends more on administration benefit, manufacturing reliability, and contracting than on the prochlorperazine molecule.
• A 505(b)(2) strategy may be appropriate for a new route or delivery system that cannot fit a conventional ANDA pathway.

FAQs

Can prochlorperazine be formulated as an orally disintegrating tablet?

Yes. The principal development issues are bitterness, rapid disintegration, friability, dose uniformity, and bioequivalence. Mannitol, crospovidone, croscarmellose sodium, and taste-masking technologies are plausible excipient tools.

Is a prochlorperazine oral liquid commercially attractive?

It can be attractive for pediatric, geriatric, and dysphagic patients. The product must address chemical stability, preservative efficacy, dose measurement, flavor, and sugar- or alcohol-free positioning.

Which excipient risk is most important for injectable prochlorperazine?

Compatibility and stability are the primary risks. Sulfite sensitivity, oxidation, pH control, container interaction, sterility, and particulate formation require product-specific evaluation.

Can an excipient change support a new patent?

Yes, but the patent must claim a novel and non-obvious formulation, process, delivery system, or packaging configuration. A routine substitution of one filler or lubricant is unlikely to provide strong protection.

Is prochlorperazine a good candidate for a 505(b)(2) product?

It may be suitable when the sponsor develops a new route, delivery system, or clinically meaningful formulation advantage. A conventional tablet or equivalent generic product is more likely to fit the ANDA pathway.

References

1. U.S. National Library of Medicine. (n.d.). DailyMed: Prochlorperazine product labeling. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (n.d.). Prochlorperazine prescribing information and safety labeling. https://www.accessdata.fda.gov/

3. U.S. National Library of Medicine. (n.d.). DailyMed: Prochlorperazine edisylate injection labeling. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-approval-process-drugs/abbreviated-new-drug-application-anda-generic-drug-user-fee-amendments-fdaaa-reauthorization/505b2-applications-contained-within-nda-application-supplements-and-abbreviated-new-drug-application-anda-񎟙